Co-crystals of diflunisal and isomeric pyridinecarboxamides - a thermodynamics and crystal engineering contribution
Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach...
Saved in:
Published in | CrystEngComm Vol. 18; no. 25; pp. 4749 - 4759 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.01.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 1466-8033 1466-8033 |
DOI | 10.1039/c6ce00380j |
Cover
Abstract | Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach is used to investigate binary mixtures (diflunisal + picolinamide and diflunisal + isonicotinamide) in order to identify solid forms that are potentially useful to improve the biopharmaceutical performance of this active pharmaceutical ingredient. Special emphasis is placed on the research of co-crystals and on the influence of structural changes in the pyridinecarboxamide co-former molecules for co-crystal formation with diflunisal. The thermodynamics based methodology described by ter Horst
et al.
in 2010 indicates that the formation of co-crystals is thermodynamically feasible for both systems. The binary solid-liquid phase diagrams were built and allowed unequivocal identification of the formation of co-crystals of diflunisal with each of the two isomers and also their stoichiometry of 1 : 1, (diflunisal : co-former) in the case of pyridine-2-carboxamide (picolinamide) and (2 : 1) for pyridine-4-carboxamide (isonicotinamide). Two binary eutectic mixtures, potentially relevant for pharmaceutical application, were also identified. Infrared spectroscopy allowed the identification of the acid N-pyridine heterosynthon in the three co-crystals formed by diflunisal with the isomeric pyridinecarboxamides. However, the results clearly differentiated pyridine-2-carboxamide from pyridine-3-carboxamide and pyridine-4-carboxamide, that share similar crystalline arrangements, at least with respect to the supramolecular synthons.
A thermodynamics based investigation of diflunisal + picolinamide and diflunisal + isonicotinamide binary mixtures is presented. The influence of structural changes of pyridinecarboxamides in co-crystal formation is addressed. |
---|---|
AbstractList | Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach is used to investigate binary mixtures (diflunisal + picolinamide and diflunisal + isonicotinamide) in order to identify solid forms that are potentially useful to improve the biopharmaceutical performance of this active pharmaceutical ingredient. Special emphasis is placed on the research of co-crystals and on the influence of structural changes in the pyridinecarboxamide co-former molecules for co-crystal formation with diflunisal. The thermodynamics based methodology described by ter Horst
et al.
in 2010 indicates that the formation of co-crystals is thermodynamically feasible for both systems. The binary solid-liquid phase diagrams were built and allowed unequivocal identification of the formation of co-crystals of diflunisal with each of the two isomers and also their stoichiometry of 1 : 1, (diflunisal : co-former) in the case of pyridine-2-carboxamide (picolinamide) and (2 : 1) for pyridine-4-carboxamide (isonicotinamide). Two binary eutectic mixtures, potentially relevant for pharmaceutical application, were also identified. Infrared spectroscopy allowed the identification of the acid N-pyridine heterosynthon in the three co-crystals formed by diflunisal with the isomeric pyridinecarboxamides. However, the results clearly differentiated pyridine-2-carboxamide from pyridine-3-carboxamide and pyridine-4-carboxamide, that share similar crystalline arrangements, at least with respect to the supramolecular synthons.
A thermodynamics based investigation of diflunisal + picolinamide and diflunisal + isonicotinamide binary mixtures is presented. The influence of structural changes of pyridinecarboxamides in co-crystal formation is addressed. Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach is used to investigate binary mixtures (diflunisal + picolinamide and diflunisal + isonicotinamide) in order to identify solid forms that are potentially useful to improve the biopharmaceutical performance of this active pharmaceutical ingredient. Special emphasis is placed on the research of co-crystals and on the influence of structural changes in the pyridinecarboxamide co-former molecules for co-crystal formation with diflunisal. The thermodynamics based methodology described by ter Horst et al.in 2010 indicates that the formation of co-crystals is thermodynamically feasible for both systems. The binary solid-liquid phase diagrams were built and allowed unequivocal identification of the formation of co-crystals of diflunisal with each of the two isomers and also their stoichiometry of 1 : 1, (diflunisal : co-former) in the case of pyridine-2-carboxamide (picolinamide) and (2 : 1) for pyridine-4-carboxamide (isonicotinamide). Two binary eutectic mixtures, potentially relevant for pharmaceutical application, were also identified. Infrared spectroscopy allowed the identification of the acid...N-pyridine heterosynthon in the three co-crystals formed by diflunisal with the isomeric pyridinecarboxamides. However, the results clearly differentiated pyridine-2-carboxamide from pyridine-3-carboxamide and pyridine-4-carboxamide, that share similar crystalline arrangements, at least with respect to the supramolecular synthons. |
Author | Castro, Ricardo A. E Eusébio, M. Ermelinda S Maria, Teresa M. R Silva, M. Ramos Canotilho, João Évora, António O. L ter Horst, J. H |
AuthorAffiliation | Department of Chemistry University of Coimbra Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC) University of Strathclyde Technology and Innovation Centre Faculty of Pharmacy Department of Physics |
AuthorAffiliation_xml | – sequence: 0 name: Faculty of Pharmacy – sequence: 0 name: Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) – sequence: 0 name: Department of Chemistry – sequence: 0 name: Department of Physics – sequence: 0 name: University of Strathclyde – sequence: 0 name: EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC) – sequence: 0 name: Technology and Innovation Centre – sequence: 0 name: University of Coimbra |
Author_xml | – sequence: 1 givenname: António O. L surname: Évora fullname: Évora, António O. L – sequence: 2 givenname: Ricardo A. E surname: Castro fullname: Castro, Ricardo A. E – sequence: 3 givenname: Teresa M. R surname: Maria fullname: Maria, Teresa M. R – sequence: 4 givenname: M. Ramos surname: Silva fullname: Silva, M. Ramos – sequence: 5 givenname: J. H surname: ter Horst fullname: ter Horst, J. H – sequence: 6 givenname: João surname: Canotilho fullname: Canotilho, João – sequence: 7 givenname: M. Ermelinda S surname: Eusébio fullname: Eusébio, M. Ermelinda S |
BookMark | eNptkctLxDAQxoMouLt68S7kKEI1j222PUpZXyx40XNJp9M1S5usSRfsf2_2gYp4mpnw_b4h34zJsXUWCbng7IYzmd-CAmRMZmx1REZ8qlSSMSmPf_WnZBzCijE-5ZyNSChcAn4IvW4DdQ2tTdNurAm6pdrW1ATXoTdA14M3tbEI2lfuU3emxkATqmn_jr5z9WDjG4QddPCjaJeRiLhdUnC296ba9MbZM3LSxHV4fqgT8nY_fy0ek8XLw1Nxt0hACtknyMVMIFR1o6dK5lwhVwCsSRsUkDM-Y6molah0HDKdpbwSiuWzmECWZ1poOSFXe9-1dx8bDH3ZmQDYttqi24SSZyJNuRIij9LrvRS8C8FjU6696bQfSs7KbbJloYr5LtnnKGZ_xGB6vf1Z77Vp_0cu94gP8G39cyz5BcdxiWQ |
CitedBy_id | crossref_primary_10_1016_j_ijpharm_2021_120605 crossref_primary_10_1016_j_ejps_2019_01_007 crossref_primary_10_1002_chem_201904130 crossref_primary_10_3390_cryst9020070 crossref_primary_10_1016_j_ijpharm_2024_124959 crossref_primary_10_3390_pharmaceutics12111098 crossref_primary_10_2174_1381612826666200523173448 crossref_primary_10_1007_s10973_017_6474_2 crossref_primary_10_1016_j_ijpharm_2021_120441 crossref_primary_10_1021_acs_cgd_6b01154 crossref_primary_10_3390_pharmaceutics13122081 crossref_primary_10_1016_j_partic_2021_03_015 crossref_primary_10_1039_C6CE01835A |
Cites_doi | 10.1039/J19660000439 10.1021/cg800173d 10.1039/C4CE00265B 10.1002/jps.21280 10.1107/S0365110X66003396 10.1016/j.molstruc.2003.07.010 10.1021/mp0600182 10.1039/b818268j 10.1021/cg701024c 10.1039/c2ce26244d 10.1039/b313552g 10.1039/C5CC08216A 10.1039/b402150a 10.1039/C0CC04117C 10.1107/S0021889810054725 10.1039/B612353H 10.1351/pac200678071455 10.1021/cg2009946 10.1039/c2cc18025a 10.1021/op400182k 10.1016/S1056-8719(00)00107-6 10.1002/jps.23402 10.1021/cg025593z 10.1002/anie.201302814 10.1021/cg901230b 10.1002/jps.22234 10.1039/c3ce40286j 10.1039/b315687g 10.1080/01496399508010394 10.3109/13506129.2012.678509 10.1021/cg025589n 10.1021/cg801200h 10.1016/S0378-5173(00)00505-6 10.1021/jp101303j 10.1071/CH05270 10.1007/s11095-006-9032-3 10.1021/cg070218y 10.1039/b708112j 10.1021/cg200288b 10.1016/j.ejps.2014.06.017 10.1039/C3CC47521B 10.1016/j.ijpharm.2014.02.048 10.1039/c1ce06320k 10.1039/a806387g 10.1039/c3ce41013g 10.1039/c2ce06391c 10.1016/0040-6031(90)80235-Q 10.1016/0040-6031(95)02717-3 10.1002/jps.20578 |
ContentType | Journal Article |
DBID | AAYXX CITATION 7U5 8FD L7M |
DOI | 10.1039/c6ce00380j |
DatabaseName | CrossRef Solid State and Superconductivity Abstracts Technology Research Database Advanced Technologies Database with Aerospace |
DatabaseTitle | CrossRef Technology Research Database Advanced Technologies Database with Aerospace Solid State and Superconductivity Abstracts |
DatabaseTitleList | Technology Research Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1466-8033 |
EndPage | 4759 |
ExternalDocumentID | 10_1039_C6CE00380J c6ce00380j |
GroupedDBID | -JG 0-7 0R~ 29F 4.4 5GY 6J9 705 70~ 7~J AAEMU AAIWI AAJAE AAMEH AANOJ AAWGC AAXHV AAXPP ABASK ABDVN ABEMK ABJNI ABPDG ABRYZ ABXOH ACGFO ACGFS ACLDK ADMRA ADSRN AEFDR AENEX AENGV AESAV AETIL AFLYV AFOGI AFVBQ AGEGJ AGKEF AGRSR AGSTE AHGCF ALMA_UNASSIGNED_HOLDINGS ANBJS ANUXI APEMP ASKNT AUDPV AZFZN BLAPV BSQNT C6K CS3 E3Z EBS ECGLT EE0 EF- EJD GGIMP GNO H13 HZ~ H~N IDZ J3I N9A O9- OK1 P2P R7B RAOCF RCNCU RNS ROL RPMJG RRA RRC RSCEA SKA SLH VH6 0UZ 1TJ 71~ AAYXX ACHDF ACRPL ADNMO AFRZK AGQPQ AHGXI AKMSF ALSGL ANLMG ASPBG AVWKF BBWZM CAG CITATION COF EEHRC FEDTE HVGLF IDY J3G J3H L-8 M4U NDZJH R56 RCLXC 7U5 8FD L7M |
ID | FETCH-LOGICAL-c323t-e1272ecbdfa463916e16cc0f5fe2c9017052d62bac908a851b260976ce898a2a3 |
ISSN | 1466-8033 |
IngestDate | Fri Jul 11 10:53:52 EDT 2025 Tue Jul 01 02:20:43 EDT 2025 Thu Apr 24 23:00:15 EDT 2025 Tue Dec 17 20:59:51 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 25 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c323t-e1272ecbdfa463916e16cc0f5fe2c9017052d62bac908a851b260976ce898a2a3 |
Notes | 10.1039/c6ce00380j Electronic supplementary information (ESI) available. See DOI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PQID | 1825516229 |
PQPubID | 23500 |
PageCount | 11 |
ParticipantIDs | rsc_primary_c6ce00380j crossref_citationtrail_10_1039_C6CE00380J crossref_primary_10_1039_C6CE00380J proquest_miscellaneous_1825516229 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-01-01 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | CrystEngComm |
PublicationYear | 2016 |
References | Brittain (C6CE00380J-(cit12)/*[position()=1]) 2013; 102 ter Horst (C6CE00380J-(cit37)/*[position()=1]) 2009; 9 Vishweshwar (C6CE00380J-(cit5)/*[position()=1]) 2006; 95 Habgood (C6CE00380J-(cit34)/*[position()=1]) 2010; 10 Eccles (C6CE00380J-(cit44)/*[position()=1]) 2011; 13 Cherukuvada (C6CE00380J-(cit25)/*[position()=1]) 2012; 14 Della Gatta (C6CE00380J-(cit48)/*[position()=1]) 2006; 78 Évora (C6CE00380J-(cit31)/*[position()=1]) 2012 Bond (C6CE00380J-(cit3)/*[position()=1]) 2007; 9 Brittain (C6CE00380J-(cit6)/*[position()=1]) 2013; 102 Nigond (C6CE00380J-(cit24)/*[position()=1]) 1995; 30 Corvis (C6CE00380J-(cit51)/*[position()=1]) 2010; 114 Duggirala (C6CE00380J-(cit21)/*[position()=1]) 2016; 52 Chadwick (C6CE00380J-(cit36)/*[position()=1]) 2009; 11 Cassidy (C6CE00380J-(cit57)/*[position()=1]) 1999 Castaneda (C6CE00380J-(cit58)/*[position()=1]) 2003; 660 Kulkarni (C6CE00380J-(cit46)/*[position()=1]) 2012; 48 Hadzi (C6CE00380J-(cit59)/*[position()=1]) 1966 Juncher (C6CE00380J-(cit13)/*[position()=1]) 1957; 4 Evora (C6CE00380J-(cit41)/*[position()=1]) 2012; 14 Dunitz (C6CE00380J-(cit4)/*[position()=1]) 2003; 5 Choquesillo-Lazarte (C6CE00380J-(cit61)/*[position()=1]) 2011; 44 Evora (C6CE00380J-(cit11)/*[position()=1]) 2011; 11 Meanwell (C6CE00380J-(cit10)/*[position()=1]) 2008; vol. 43 Prigogine (C6CE00380J-(cit56)/*[position()=1]) 1954 Sabbah (C6CE00380J-(cit47)/*[position()=1]) 1999; 331 Cherukuvada (C6CE00380J-(cit26)/*[position()=1]) 2014; 50 Dorn (C6CE00380J-(cit23)/*[position()=1]) 2006; 59 Almarsson (C6CE00380J-(cit14)/*[position()=1]) 2004 Chen (C6CE00380J-(cit19)/*[position()=1]) 2007 Lipinski (C6CE00380J-(cit15)/*[position()=1]) 2000; 44 Aakeroy (C6CE00380J-(cit43)/*[position()=1]) 2003; 3 Seaton (C6CE00380J-(cit29)/*[position()=1]) 2009; 9 Kang (C6CE00380J-(cit52)/*[position()=1]) 2000; 206 Chiarella (C6CE00380J-(cit35)/*[position()=1]) 2007; 7 Hohne (C6CE00380J-(cit53)/*[position()=1]) 1990; 160 Bak (C6CE00380J-(cit17)/*[position()=1]) 2008; 97 Wang (C6CE00380J-(cit32)/*[position()=1]) 2013; 17 Berk (C6CE00380J-(cit28)/*[position()=1]) 2012; 19 Wouters (C6CE00380J-(cit9)/*[position()=1]) 2012 Bucar (C6CE00380J-(cit8)/*[position()=1]) 2013; 15 Lemke (C6CE00380J-(cit20)/*[position()=1]) 2008 Takagi (C6CE00380J-(cit22)/*[position()=1]) 2006; 3 Takano (C6CE00380J-(cit42)/*[position()=1]) 1966; 21 Desiraju (C6CE00380J-(cit2)/*[position()=1]) 2003; 5 Landenberger (C6CE00380J-(cit7)/*[position()=1]) 2013; 52 Castro (C6CE00380J-(cit39)/*[position()=1]) 2011; 11 Li (C6CE00380J-(cit45)/*[position()=1]) 2011; 47 Évora (C6CE00380J-(cit30)/*[position()=1]) 2014 Holan (C6CE00380J-(cit38)/*[position()=1]) 2014; 63 Cross (C6CE00380J-(cit40)/*[position()=1]) 2003; 3 Chan (C6CE00380J-(cit33)/*[position()=1]) 2014; 16 Gallis (C6CE00380J-(cit54)/*[position()=1]) 1996; 274 Stanton (C6CE00380J-(cit16)/*[position()=1]) 2008; 8 McNamara (C6CE00380J-(cit18)/*[position()=1]) 2006; 23 Le Minh (C6CE00380J-(cit55)/*[position()=1]) 2010; 99 Mukherjee (C6CE00380J-(cit60)/*[position()=1]) 2013; 15 |
References_xml | – issn: 2012 publication-title: Pharmaceutical Salts and Co-crystals doi: Wouters Quéré – issn: 2008 issue: vol. 43 end-page: p 373-404 publication-title: Annu. Rep. Med. Chem. doi: Meanwell – issn: 1954 publication-title: Chemical Thermodynamics doi: Prigogine Defay – issn: 2012 publication-title: Binary solid-liquid phase diagrams of diflunisal and pyridinecarboxamides doi: Évora Castro Maria Rosado Silva Canotilho Eusébio – issn: 2008 publication-title: Foye's Principles of Medicinal Chemistry doi: Lemke Williams Roche Zito – volume-title: Pharmaceutical Salts and Co-crystals year: 2012 ident: C6CE00380J-(cit9)/*[position()=1] – start-page: 439 year: 1966 ident: C6CE00380J-(cit59)/*[position()=1] publication-title: J. Chem. Soc. A doi: 10.1039/J19660000439 – volume: 8 start-page: 3856 year: 2008 ident: C6CE00380J-(cit16)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg800173d – volume: 16 start-page: 4365 year: 2014 ident: C6CE00380J-(cit33)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/C4CE00265B – volume: 97 start-page: 3942 year: 2008 ident: C6CE00380J-(cit17)/*[position()=1] publication-title: J. Pharm. Sci. doi: 10.1002/jps.21280 – volume: 21 start-page: 514 year: 1966 ident: C6CE00380J-(cit42)/*[position()=1] publication-title: Acta Crystallogr. doi: 10.1107/S0365110X66003396 – volume: 660 start-page: 25 year: 2003 ident: C6CE00380J-(cit58)/*[position()=1] publication-title: J. Mol. Struct. doi: 10.1016/j.molstruc.2003.07.010 – volume: 3 start-page: 631 year: 2006 ident: C6CE00380J-(cit22)/*[position()=1] publication-title: Mol. Pharmaceutics doi: 10.1021/mp0600182 – volume: 11 start-page: 412 year: 2009 ident: C6CE00380J-(cit36)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/b818268j – volume: 9 start-page: 47 year: 2009 ident: C6CE00380J-(cit29)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg701024c – volume: 14 start-page: 8649 year: 2012 ident: C6CE00380J-(cit41)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/c2ce26244d – volume: 5 start-page: 466 year: 2003 ident: C6CE00380J-(cit2)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/b313552g – volume-title: Chemical Thermodynamics year: 1954 ident: C6CE00380J-(cit56)/*[position()=1] – volume: 52 start-page: 640 year: 2016 ident: C6CE00380J-(cit21)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/C5CC08216A – start-page: 1889 year: 2004 ident: C6CE00380J-(cit14)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/b402150a – volume: 47 start-page: 1530 year: 2011 ident: C6CE00380J-(cit45)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/C0CC04117C – volume: 44 start-page: 172 year: 2011 ident: C6CE00380J-(cit61)/*[position()=1] publication-title: J. Appl. Crystallogr. doi: 10.1107/S0021889810054725 – volume-title: Binary solid–liquid phase diagrams of diflunisal and pyridinecarboxamides year: 2012 ident: C6CE00380J-(cit31)/*[position()=1] – start-page: 419 year: 2007 ident: C6CE00380J-(cit19)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/B612353H – volume: vol. 43 volume-title: Annu. Rep. Med. Chem. year: 2008 ident: C6CE00380J-(cit10)/*[position()=1] – volume: 78 start-page: 1455 year: 2006 ident: C6CE00380J-(cit48)/*[position()=1] publication-title: Pure Appl. Chem. doi: 10.1351/pac200678071455 – volume: 11 start-page: 5396 year: 2011 ident: C6CE00380J-(cit39)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg2009946 – volume: 48 start-page: 4983 year: 2012 ident: C6CE00380J-(cit46)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/c2cc18025a – volume: 17 start-page: 1413 year: 2013 ident: C6CE00380J-(cit32)/*[position()=1] publication-title: Org. Process Res. Dev. doi: 10.1021/op400182k – volume-title: Foye's Principles of Medicinal Chemistry year: 2008 ident: C6CE00380J-(cit20)/*[position()=1] – volume: 44 start-page: 235 year: 2000 ident: C6CE00380J-(cit15)/*[position()=1] publication-title: J. Pharmacol. Toxicol. Methods doi: 10.1016/S1056-8719(00)00107-6 – volume: 102 start-page: 311 year: 2013 ident: C6CE00380J-(cit12)/*[position()=1] publication-title: J. Pharm. Sci. doi: 10.1002/jps.23402 – volume: 3 start-page: 159 year: 2003 ident: C6CE00380J-(cit43)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg025593z – volume: 52 start-page: 6468 year: 2013 ident: C6CE00380J-(cit7)/*[position()=1] publication-title: Angew. Chem., Int. Ed. doi: 10.1002/anie.201302814 – volume: 10 start-page: 903 year: 2010 ident: C6CE00380J-(cit34)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg901230b – volume: 99 start-page: 4084 year: 2010 ident: C6CE00380J-(cit55)/*[position()=1] publication-title: J. Pharm. Sci. doi: 10.1002/jps.22234 – volume: 15 start-page: 4640 year: 2013 ident: C6CE00380J-(cit60)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/c3ce40286j – volume: 5 start-page: 506 year: 2003 ident: C6CE00380J-(cit4)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/b315687g – volume: 30 start-page: 2075 year: 1995 ident: C6CE00380J-(cit24)/*[position()=1] publication-title: Sep. Sci. Technol. doi: 10.1080/01496399508010394 – volume: 19 start-page: 37 year: 2012 ident: C6CE00380J-(cit28)/*[position()=1] publication-title: Amyloid doi: 10.3109/13506129.2012.678509 – volume: 3 start-page: 151 year: 2003 ident: C6CE00380J-(cit40)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg025589n – volume: 9 start-page: 1531 year: 2009 ident: C6CE00380J-(cit37)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg801200h – volume: 206 start-page: 35 year: 2000 ident: C6CE00380J-(cit52)/*[position()=1] publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(00)00505-6 – volume: 4 start-page: 497 year: 1957 ident: C6CE00380J-(cit13)/*[position()=1] publication-title: Antibiot. Med. Clin. Ther. – volume: 114 start-page: 5420 year: 2010 ident: C6CE00380J-(cit51)/*[position()=1] publication-title: J. Phys. Chem. B doi: 10.1021/jp101303j – volume: 331 start-page: 93 year: 1999 ident: C6CE00380J-(cit47)/*[position()=1] publication-title: Acta – volume: 59 start-page: 22 year: 2006 ident: C6CE00380J-(cit23)/*[position()=1] publication-title: Aust. J. Chem. doi: 10.1071/CH05270 – volume: 23 start-page: 1888 year: 2006 ident: C6CE00380J-(cit18)/*[position()=1] publication-title: Pharm. Res. doi: 10.1007/s11095-006-9032-3 – volume: 7 start-page: 1223 year: 2007 ident: C6CE00380J-(cit35)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg070218y – volume: 9 start-page: 833 year: 2007 ident: C6CE00380J-(cit3)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/b708112j – volume: 11 start-page: 4780 year: 2011 ident: C6CE00380J-(cit11)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg200288b – volume: 63 start-page: 124 year: 2014 ident: C6CE00380J-(cit38)/*[position()=1] publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2014.06.017 – volume: 50 start-page: 906 year: 2014 ident: C6CE00380J-(cit26)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/C3CC47521B – volume: 102 start-page: 311 year: 2013 ident: C6CE00380J-(cit6)/*[position()=1] publication-title: J. Pharm. Sci. doi: 10.1002/jps.23402 – start-page: 68 year: 2014 ident: C6CE00380J-(cit30)/*[position()=1] publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2014.02.048 – volume: 13 start-page: 6923 year: 2011 ident: C6CE00380J-(cit44)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/c1ce06320k – start-page: 635 year: 1999 ident: C6CE00380J-(cit57)/*[position()=1] publication-title: J. Chem. Soc., Perkin Trans. 2 doi: 10.1039/a806387g – volume: 15 start-page: 6289 year: 2013 ident: C6CE00380J-(cit8)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/c3ce41013g – volume: 14 start-page: 2579 year: 2012 ident: C6CE00380J-(cit25)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/c2ce06391c – volume: 160 start-page: 1 year: 1990 ident: C6CE00380J-(cit53)/*[position()=1] publication-title: Thermochim. Acta doi: 10.1016/0040-6031(90)80235-Q – volume: 274 start-page: 223 year: 1996 ident: C6CE00380J-(cit54)/*[position()=1] publication-title: Thermochim. Acta doi: 10.1016/0040-6031(95)02717-3 – volume: 95 start-page: 499 year: 2006 ident: C6CE00380J-(cit5)/*[position()=1] publication-title: J. Pharm. Sci. doi: 10.1002/jps.20578 |
SSID | ssj0014110 |
Score | 2.2154787 |
Snippet | Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed... |
SourceID | proquest crossref rsc |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 4749 |
SubjectTerms | Drugs Formations Ingredients Isomers Pharmaceuticals Phase diagrams Therapy Thermodynamics |
Title | Co-crystals of diflunisal and isomeric pyridinecarboxamides - a thermodynamics and crystal engineering contribution |
URI | https://www.proquest.com/docview/1825516229 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELW63QscEF8rygIygguKUhrbSZNjiYqWFQUJutLeIsdxUFAbr5J0l-XXM47zVVEk4BK1tuND3pNnxuN5Rui166cMAjZhz4Sf2ix1Ajt2nNj2uYzBYEl3HugC59Un7-yCnV-6l6PRzbC6pIqn4ufBupL_QRXaAFddJfsPyHaTQgP8BnzhCQjD868wDpUtilvw74wEcpKlmzo7bcr_s1KZg_JXt0UGJkoKXsTqB99miSwt2-La6Sy2KjGX0hux5mY-S_Y6heY4e3Mv1tCZDfXYZf5NF5m0wOnEux9cq4I30gS64R3NM2V9nlrdTnPIy8pU2HwBlhSJshbTvihiBQF8_f5aFrLk1mran2v8mm2u6z7dyLdqb9_CGe5bSLPWMk9rIRsdjN8X411bEt0srWxutE0bM611Cg-agBnVCqrCE1JnPWffe0PXHT_sO4_QMZmD0zVGx4vl-sPHLgHFwC1q1Wxp8LZ_Y99_6YOSo6K9Mab2TNb30b0mpMALw48HaCTzh-juQGjyESoHTMEqxT1TMICOW6bgQ0zBNuZ4nyn1S818eMAUPGTKY3TxfrkOz-zmug1bUEIrWzpkTqSIk5QzT9djS8cTYpa6qSQiqHWXSOKRmMMfn4OnHkMsDN6skH7gc8LpCRrnKpdPEGbQmJBUgPFi4I-7gUwpAOYlDuUJm9EJetN-xEg0WvT6SpRNVJ-JoEEUeuGy_uDnE_SqG3tlFFgOjnrZYhHBAqmzXjyXaldGEEDrZDAhwQSdAEjdJD2mT__UcYru9NR9hsZVsZPPwQmt4hcNYX4Bf-aNNw |
linkProvider | Royal Society of Chemistry |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Co-crystals+of+diflunisal+and+isomeric+pyridinecarboxamides+-+a+thermodynamics+and+crystal+engineering+contribution&rft.jtitle=CrystEngComm&rft.au=%C3%89vora%2C+Ant%C3%B3nio+O.+L&rft.au=Castro%2C+Ricardo+A.+E&rft.au=Maria%2C+Teresa+M.+R&rft.au=Silva%2C+M.+Ramos&rft.date=2016-01-01&rft.eissn=1466-8033&rft.volume=18&rft.issue=25&rft.spage=4749&rft.epage=4759&rft_id=info:doi/10.1039%2Fc6ce00380j&rft.externalDocID=c6ce00380j |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1466-8033&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1466-8033&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1466-8033&client=summon |